ECM

Daily IPOs & Placements: AsiaInfo Tech (亚信科技) IPO: What You Need to Know Before the Trading Debut and more

In this briefing:

  1. AsiaInfo Tech (亚信科技) IPO: What You Need to Know Before the Trading Debut
  2. Softbank Corp IPO – Trading Strategies
  3. Metropolis Healthcare Pre-IPO Quick Take – Steady Performance but Growth Lagged Network Expansion
  4. SoftBank Corp IPO Valuation: Bull/Bear Case DCF Scenarios
  5. Luzhou City Commercial Bank IPO (泸州市商业银行) Trading Update – Low Liquidity, as Expected

1. AsiaInfo Tech (亚信科技) IPO: What You Need to Know Before the Trading Debut

Valuation%20dec%2018thpng

AsiaInfo Tech priced its IPO at HKD 10.50/share and will start trading today. Prior to the trading debut, in this short note, we summarize the latest information with updates on our valuation. 


Our Previous Insight on AsiaInfo Tech:

2. Softbank Corp IPO – Trading Strategies

Performance returns since 4th december chartbuilder

Bloomberg reported Softbank Corp (9434 JP)‘s international bookbuild was 2 – 3x covered while retail offering was at almost 2x. There were other reports of bookrunners struggling to sell shares to retail investors.

In this insight, we will look at how peers and market have performed since bookbuild and provide a sensitivity table with implied valuations for different price points and thoughts on the price range for near-term trading. 


We have already covered most aspects of Softbank Corp (9434 JP) ‘s IPO in our previous insights:

3. Metropolis Healthcare Pre-IPO Quick Take – Steady Performance but Growth Lagged Network Expansion

Financials%20 %20cash%20flow%20details

Metropolis Health Services Limited (MHL IN) (MHL) plans to raise US$100m+ in its Indian IPO. MHL is one of the largest diagnostic chains in the country. Carlyle invested in the company in 2015. 

MHL has registered steady growth and margins over the past few years. It has also aggressively expanded its network over the past few years, although revenue growth hasn’t matched the network expansion.

MHL’s recent financial performance has been in-line with its listed peers, Dr Lal Pathlabs (DLPL IN) and Thyrocare Technologies (THYROCAR IN), while the company continues to lead its two listed peers in terms of revenue generated per test.

4. SoftBank Corp IPO Valuation: Bull/Bear Case DCF Scenarios

Dcf

Softbank Group (9984 JP) is set to raise JPY2.65 trillion ($23.5 billion) through the Softbank Corp (9434 JP) IPO, Japan’s biggest-ever IPO. However, SoftBank Corp’s IPO which is set for 19 December is oversubscribed by less than double, according to press reports. This level of oversubscription is well below blockbuster Japanese stock debuts such as Mercari Inc (4385 JP) and Recruit Holdings (6098 JP).

Based on client discussion on SoftBank Corp’s intrinsic value, we have put together a DCF-based valuation along with scenario analysis. Our conclusion remains the same that SoftBank Corp is overvalued at the proposed IPO price of JPY1,500 per share. 

5. Luzhou City Commercial Bank IPO (泸州市商业银行) Trading Update – Low Liquidity, as Expected

Subsciption

Luzhou Commercial Bank Co Ltd (1983 HK) IPO raised about US$222m at HKD3.18 per share, close to the bottom end of its price range. We have covered the IPO in our previous insight, Luzhou City Commercial Bank IPO (泸州市商业银行) – Earnings Lagging Asset Growth Owing to Tightening Spread.

In this insight, we will update on the deal dynamics, implied valuation, and include a valuation sensitivity table.